{"id":8416,"date":"2026-06-16T14:41:05","date_gmt":"2026-06-16T14:41:05","guid":{"rendered":"https:\/\/www.pezcoller.it\/?page_id=8416"},"modified":"2026-08-26T09:16:26","modified_gmt":"2026-08-26T09:16:26","slug":"borsisti-fondazione-pezcoller-sic","status":"publish","type":"page","link":"https:\/\/www.pezcoller.it\/it\/borsisti-fondazione-pezcoller-sic\/","title":{"rendered":"Borsisti Fondazione Pezcoller-SIC"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_5,2_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.7&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#951542&#8243; header_2_font=&#8221;Lato|700|||||||&#8221; header_2_text_color=&#8221;#83004A&#8221; header_2_font_size=&#8221;30px&#8221; hover_enabled=&#8221;0&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<h2>Le ricerche dei borsisti Pezcoller-SIC<\/h2>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.7&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;15px&#8221; header_3_font=&#8221;Lato|600|||||||&#8221; header_3_text_color=&#8221;#83004A&#8221; header_3_font_size=&#8221;19px&#8221; custom_margin=&#8221;-13px|||||&#8221; hover_enabled=&#8221;0&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<h3>Borse 2025-2026<\/h3>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;3_5,2_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;-17px|auto||auto||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;15px&#8221; header_3_font=&#8221;Lato|600|||||||&#8221; header_3_text_color=&#8221;#951542&#8243; header_3_font_size=&#8221;19px&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span style=\"color: #494949; font-size: large;\"><strong>GABRIELE ANTONARELLI<\/strong> (Istituto Europeo di Oncologia, Milano)<\/span><\/p>\n<p><em><span style=\"color: #494949; font-size: medium;\">&#8220;Ricerca di biomarcatori per prevedere la tossicit\u00e0 del Trastuzumab- <\/span><\/em><em><span style=\"color: #494949; font-size: medium;\">Deruxtecan (T-DXd) in pazienti affetti da carcinoma mammario <\/span><\/em><em><span style=\"color: #494949; font-size: medium;\">avanzato. Tox-DXd: uno studio osservazionale, non-interventistico&#8221;<\/span><\/em><\/p>\n<p><span style=\"color: #494949; font-size: medium;\">Il suo progetto mira a identificare biomarcatori in grado di prevedere gli<\/span><br \/><span style=\"color: #494949; font-size: medium;\">eventi avversi del trattamento con Trastuzumab-deruxtecan nel <span style=\"color: #951542;\"><strong>carcinoma <\/strong><\/span><\/span><span style=\"color: #494949; font-size: medium;\"><span style=\"color: #951542;\"><strong>mammario avanzato<\/strong><\/span>. La ricerca include un\u2019<strong>analisi retrospettiva <\/strong><\/span><span style=\"color: #494949; font-size: medium;\"><strong>su 112 pazienti<\/strong>, recentemente pubblicata su ESMO Open, e una fase <\/span><span style=\"color: #494949; font-size: medium;\">prospettica con il <strong>monitoraggio di 84 pazienti<\/strong>.<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/www.pezcoller.it\/wp-content\/uploads\/2026\/03\/gabriele-antonarelli.jpg&#8221; title_text=&#8221;gabriele-antonarelli&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; width=&#8221;58%&#8221; max_width=&#8221;100%&#8221; custom_margin=&#8221;-3px|||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;3_5,2_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;-17px|auto||auto||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;15px&#8221; header_3_font=&#8221;Lato|600|||||||&#8221; header_3_text_color=&#8221;#951542&#8243; header_3_font_size=&#8221;19px&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span style=\"color: #494949; font-size: large;\"><strong>LUCREZIA CAMICIA<\/strong> (Centro di Riferimento Oncologico, Aviano)<\/span><\/p>\n<p><span style=\"color: #494949;\"><em><span style=\"font-size: medium;\">&#8220;Ruolo di Multimerina-2 nella regolazione della stabilit\u00e0 vascolare tumorale nella risposta alla chemio\/ immunoterapia&#8221;<\/span><\/em><\/span><\/p>\n<p><span style=\"color: #494949;\">Multimerin-2 \u00e8 una proteina della matrice extracellulare importante per <span style=\"color: #951542;\"><strong>la salute dei vasi sanguigni<\/strong><\/span>, un fattore importante per <strong>valutare l\u2019efficacia delle terapie antitumorali<\/strong>. Il nostro studio mira a studiare il suo ruolo come possibile biomarcatore, per <strong>r<\/strong><\/span><strong><span style=\"color: #494949;\">endere <\/span>i trattamenti sempre pi\u00f9 efficaci<\/strong>.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/www.pezcoller.it\/wp-content\/uploads\/2026\/03\/lucrezia-camicia.jpg&#8221; title_text=&#8221;lucrezia-camicia&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; width=&#8221;58%&#8221; max_width=&#8221;100%&#8221; custom_margin=&#8221;-3px|||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;3_5,2_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;-17px|auto||auto||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;15px&#8221; header_3_font=&#8221;Lato|600|||||||&#8221; header_3_text_color=&#8221;#951542&#8243; header_3_font_size=&#8221;19px&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span style=\"color: #494949; font-size: large;\"><strong>MATTIA COLUCCI <\/strong>(Casa Sollievo Sofferenza, S. Giovanni Rotondo)<\/span><\/p>\n<p><em><span style=\"color: #494949;\">&#8220;Il ruolo funzionale dell\u2019inattivazione di EZH2 nella patogenesi della leucemia linfoblastica acuta a cellule T con aumento d\u2019espressione dei geni del gruppo HOXA&#8221;<\/span><\/em><\/p>\n<p>Il progetto si propone di approfondire i meccanismi molecolari di <strong>una forma aggressiva di <span style=\"color: #951542;\">leucemia infantile<\/span><\/strong> (ETP-ALL). Si indaga come la <strong>combinazione di alterazioni genetiche<\/strong> promuova la malattia, con l\u2019obiettivo di identificare nuovi bersagli terapeutici per sviluppare <strong>cure pi\u00f9 efficaci e meno tossiche<\/strong> per i giovani pazienti.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/www.pezcoller.it\/wp-content\/uploads\/2025\/07\/colucci.jpg&#8221; title_text=&#8221;colucci&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; width=&#8221;58%&#8221; max_width=&#8221;100%&#8221; custom_margin=&#8221;-3px|||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;3_5,2_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;-17px|auto||auto||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;15px&#8221; header_3_font=&#8221;Lato|600|||||||&#8221; header_3_text_color=&#8221;#951542&#8243; header_3_font_size=&#8221;19px&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span style=\"color: #494949; font-size: large;\"><strong>ANDREA COSTAMAGNA<\/strong>\u00a0(Universit\u00e0 di Torino)<\/span><\/p>\n<p><span style=\"color: #494949;\"><em><span style=\"font-size: medium;\">&#8220;Ruolo di p130Cas nella disseminazione iniziale del tumore del pancreas&#8221;<\/span><\/em><\/span><\/p>\n<p><span style=\"color: #494949;\">Il <span style=\"color: #951542;\"><strong>ca<\/strong><strong><span style=\"color: #951542;\">rcinoma <\/span>duttale pancreatico<\/strong><\/span> \u00e8 tra i tumori pi\u00f9 aggressivi per la sua elevata capacit\u00e0 metastatica. Il progetto indaga come la proteina p130Cas, attivata dall\u2019oncogene Kras mutato, favorisca la<strong> diffusione precoce delle cellule tumorali<\/strong> tramite la via di segnalazione PI3K-AKT,<br \/>individuando possibili <strong>vulnerabilit\u00e0<\/strong> <strong>terapeutiche<\/strong>.<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/www.pezcoller.it\/wp-content\/uploads\/2026\/03\/andrea-costamagna.jpg&#8221; title_text=&#8221;andrea-costamagna&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; width=&#8221;58%&#8221; max_width=&#8221;100%&#8221; custom_margin=&#8221;-3px|||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;3_5,2_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;-17px|auto||auto||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;15px&#8221; header_3_font=&#8221;Lato|600|||||||&#8221; header_3_text_color=&#8221;#951542&#8243; header_3_font_size=&#8221;19px&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span style=\"color: #494949; font-size: large;\"><strong>MARIA VALERIA GIULI <\/strong>(Universit\u00e0 La Sapienza, Roma)<\/span><\/p>\n<p><span style=\"color: #494949;\"><em><span style=\"font-size: medium;\">&#8220;Un nuovo modo per rendere pi\u00f9 efficace la terapia del carcinoma ovarico: imitare l\u2019effetto delle mutazioni dei geni BRCA bloccando Pin1&#8221;<\/span><\/em><\/span><\/p>\n<p><span style=\"color: #494949;\">Il<span style=\"color: #951542;\"><strong> cancro dell\u2019ovaio<\/strong><\/span> \u00e8 tra le neoplasie femminili pi\u00f9 letali per l\u2019elevata resistenza alle terapie. Lo studio delle mutazioni dei geni BRCA ha migliorato i trattamenti. La ricerca indaga Pin1, un enzima che regola la funzione di molte proteine tra le quali BRCA1, come bersaglio terapeutico<br \/>per <strong>potenziare le cure<\/strong> anche nelle pazienti senza mutazioni BRCA.<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/www.pezcoller.it\/wp-content\/uploads\/2026\/03\/maria-valeria-giuli.jpg&#8221; title_text=&#8221;maria-valeria-giuli&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; width=&#8221;58%&#8221; max_width=&#8221;100%&#8221; custom_margin=&#8221;-3px|||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;3_5,2_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;-17px|auto||auto||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;15px&#8221; header_3_font=&#8221;Lato|600|||||||&#8221; header_3_text_color=&#8221;#951542&#8243; header_3_font_size=&#8221;19px&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span style=\"color: #494949; font-size: large;\"><strong>TANIA PORCELLI<\/strong> (Universit\u00e0 di Palermo)<\/span><\/p>\n<p><span style=\"color: #494949;\"><em><span style=\"font-size: medium;\">&#8220;L\u2019obesit\u00e0 favorisce la creazione di un microambiente permissivo all\u2019 iniziazione tumorale&#8221;<\/span><\/em><\/span><\/p>\n<p><span style=\"color: #494949;\">Nel contesto del <span style=\"color: #951542;\"><strong>cancro al seno<\/strong><\/span>, il tessuto adiposo in <strong>condizioni di obesit\u00e0<\/strong> subisce cambiamenti disfunzionali che favoriscono l\u2019insorgenza di <strong>alterazioni pre-maligne<\/strong> e la progressione del tumore. Comprendere questi meccanismi contribuir\u00e0 allo sviluppo di nuove strategie terapeutiche.<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/www.pezcoller.it\/wp-content\/uploads\/2025\/01\/porcelli-gaetana.jpg&#8221; title_text=&#8221;porcelli-gaetana&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; width=&#8221;58%&#8221; max_width=&#8221;100%&#8221; custom_margin=&#8221;-3px|||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;3_5,2_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;-17px|auto||auto||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;15px&#8221; header_3_font=&#8221;Lato|600|||||||&#8221; header_3_text_color=&#8221;#951542&#8243; header_3_font_size=&#8221;19px&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span style=\"color: #494949; font-size: large;\"><strong>JESSICA RUZZOLINI<\/strong> (Universit\u00e0 di Firenze)<\/span><\/p>\n<p><span style=\"color: #494949;\"><em><span style=\"font-size: medium;\">&#8220;YAP\/TAZ come bersaglio molecolare per contrastare la resistenza farmacologica in cellule di melanoma presentanti la mutazione BRAF(V600E)&#8221;<\/span><\/em><\/span><\/p>\n<p><span style=\"color: #494949;\">Il <span style=\"color: #951542;\"><strong>melanoma<\/strong> <\/span>\u00e8 un tumore della pelle molto aggressivo e sempre pi\u00f9 diffuso. Identificare nuovi bersagli terapeutici per <strong>contrastare la resistenza farmacologica<\/strong> risulta fondamentale per lo <strong>sviluppo di trattamenti pi\u00f9 efficaci e funzionali<\/strong> all\u2019eradicazione definitiva della malattia.<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/www.pezcoller.it\/wp-content\/uploads\/2026\/03\/jessica-ruzzolini.jpg&#8221; title_text=&#8221;jessica-ruzzolini&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; width=&#8221;58%&#8221; max_width=&#8221;100%&#8221; custom_margin=&#8221;-3px|||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le ricerche dei borsisti Pezcoller-SICBorse 2025-2026GABRIELE ANTONARELLI (Istituto Europeo di Oncologia, Milano) &#8220;Ricerca di biomarcatori per prevedere la tossicit\u00e0 del Trastuzumab- Deruxtecan (T-DXd) in pazienti affetti da carcinoma mammario avanzato. Tox-DXd: uno studio osservazionale, non-interventistico&#8221; Il suo progetto mira a identificare biomarcatori in grado di prevedere glieventi avversi del trattamento con Trastuzumab-deruxtecan nel carcinoma mammario [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"give_campaign_id":0,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","yasr_overall_rating":0,"yasr_post_is_review":"","yasr_auto_insert_disabled":"","yasr_review_type":"","footnotes":""},"folder":[60],"class_list":["post-8416","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Borsisti Fondazione Pezcoller-SIC - Fondazione Pezcoller<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pezcoller.it\/it\/borsisti-fondazione-pezcoller-sic\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Borsisti Fondazione Pezcoller-SIC - Fondazione Pezcoller\" \/>\n<meta property=\"og:description\" content=\"Le ricerche dei borsisti Pezcoller-SICBorse 2025-2026GABRIELE ANTONARELLI (Istituto Europeo di Oncologia, Milano) &quot;Ricerca di biomarcatori per prevedere la tossicit\u00e0 del Trastuzumab- Deruxtecan (T-DXd) in pazienti affetti da carcinoma mammario avanzato. Tox-DXd: uno studio osservazionale, non-interventistico&quot; Il suo progetto mira a identificare biomarcatori in grado di prevedere glieventi avversi del trattamento con Trastuzumab-deruxtecan nel carcinoma mammario [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pezcoller.it\/it\/borsisti-fondazione-pezcoller-sic\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondazione Pezcoller\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/fondazionepezcoller\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-26T09:16:26+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@pezcoller\" \/>\n<meta name=\"twitter:label1\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pezcoller.it\\\/it\\\/borsisti-fondazione-pezcoller-sic\\\/\",\"url\":\"https:\\\/\\\/www.pezcoller.it\\\/it\\\/borsisti-fondazione-pezcoller-sic\\\/\",\"name\":\"Borsisti Fondazione Pezcoller-SIC - Fondazione Pezcoller\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pezcoller.it\\\/it\\\/#website\"},\"datePublished\":\"2026-06-16T14:41:05+00:00\",\"dateModified\":\"2026-08-26T09:16:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pezcoller.it\\\/it\\\/borsisti-fondazione-pezcoller-sic\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pezcoller.it\\\/it\\\/borsisti-fondazione-pezcoller-sic\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pezcoller.it\\\/it\\\/borsisti-fondazione-pezcoller-sic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pezcoller.it\\\/it\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Borsisti Fondazione Pezcoller-SIC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pezcoller.it\\\/it\\\/#website\",\"url\":\"https:\\\/\\\/www.pezcoller.it\\\/it\\\/\",\"name\":\"Fondazione Pezcoller\",\"description\":\"La ricerca di oggi \u00e8 la cura di domani\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.pezcoller.it\\\/it\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pezcoller.it\\\/it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.pezcoller.it\\\/it\\\/#organization\",\"name\":\"Fondazione Pezcoller\",\"url\":\"https:\\\/\\\/www.pezcoller.it\\\/it\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.pezcoller.it\\\/it\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.pezcoller.it\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/logo-Pezcoller_orizzontale.png\",\"contentUrl\":\"https:\\\/\\\/www.pezcoller.it\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/logo-Pezcoller_orizzontale.png\",\"width\":502,\"height\":169,\"caption\":\"Fondazione Pezcoller\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pezcoller.it\\\/it\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/fondazionepezcoller\",\"https:\\\/\\\/x.com\\\/pezcoller\",\"https:\\\/\\\/www.instagram.com\\\/fondazione_pezcoller\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@fondazionepezcoller3181\"]},false]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Borsisti Fondazione Pezcoller-SIC - Fondazione Pezcoller","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pezcoller.it\/it\/borsisti-fondazione-pezcoller-sic\/","og_locale":"it_IT","og_type":"article","og_title":"Borsisti Fondazione Pezcoller-SIC - Fondazione Pezcoller","og_description":"Le ricerche dei borsisti Pezcoller-SICBorse 2025-2026GABRIELE ANTONARELLI (Istituto Europeo di Oncologia, Milano) \"Ricerca di biomarcatori per prevedere la tossicit\u00e0 del Trastuzumab- Deruxtecan (T-DXd) in pazienti affetti da carcinoma mammario avanzato. Tox-DXd: uno studio osservazionale, non-interventistico\" Il suo progetto mira a identificare biomarcatori in grado di prevedere glieventi avversi del trattamento con Trastuzumab-deruxtecan nel carcinoma mammario [&hellip;]","og_url":"https:\/\/www.pezcoller.it\/it\/borsisti-fondazione-pezcoller-sic\/","og_site_name":"Fondazione Pezcoller","article_publisher":"https:\/\/www.facebook.com\/fondazionepezcoller","article_modified_time":"2026-08-26T09:16:26+00:00","twitter_card":"summary_large_image","twitter_site":"@pezcoller","twitter_misc":{"Tempo di lettura stimato":"7 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.pezcoller.it\/it\/borsisti-fondazione-pezcoller-sic\/","url":"https:\/\/www.pezcoller.it\/it\/borsisti-fondazione-pezcoller-sic\/","name":"Borsisti Fondazione Pezcoller-SIC - Fondazione Pezcoller","isPartOf":{"@id":"https:\/\/www.pezcoller.it\/it\/#website"},"datePublished":"2026-06-16T14:41:05+00:00","dateModified":"2026-08-26T09:16:26+00:00","breadcrumb":{"@id":"https:\/\/www.pezcoller.it\/it\/borsisti-fondazione-pezcoller-sic\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pezcoller.it\/it\/borsisti-fondazione-pezcoller-sic\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.pezcoller.it\/it\/borsisti-fondazione-pezcoller-sic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pezcoller.it\/it\/"},{"@type":"ListItem","position":2,"name":"Borsisti Fondazione Pezcoller-SIC"}]},{"@type":"WebSite","@id":"https:\/\/www.pezcoller.it\/it\/#website","url":"https:\/\/www.pezcoller.it\/it\/","name":"Fondazione Pezcoller","description":"La ricerca di oggi \u00e8 la cura di domani","publisher":{"@id":"https:\/\/www.pezcoller.it\/it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pezcoller.it\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.pezcoller.it\/it\/#organization","name":"Fondazione Pezcoller","url":"https:\/\/www.pezcoller.it\/it\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.pezcoller.it\/it\/#\/schema\/logo\/image\/","url":"https:\/\/www.pezcoller.it\/wp-content\/uploads\/2024\/11\/logo-Pezcoller_orizzontale.png","contentUrl":"https:\/\/www.pezcoller.it\/wp-content\/uploads\/2024\/11\/logo-Pezcoller_orizzontale.png","width":502,"height":169,"caption":"Fondazione Pezcoller"},"image":{"@id":"https:\/\/www.pezcoller.it\/it\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/fondazionepezcoller","https:\/\/x.com\/pezcoller","https:\/\/www.instagram.com\/fondazione_pezcoller\/","https:\/\/www.youtube.com\/@fondazionepezcoller3181"]},false]}},"yasr_visitor_votes":{"stars_attributes":{"read_only":false,"span_bottom":false},"number_of_votes":0,"sum_votes":0},"campaignId":"","_links":{"self":[{"href":"https:\/\/www.pezcoller.it\/it\/wp-json\/wp\/v2\/pages\/8416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pezcoller.it\/it\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.pezcoller.it\/it\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.pezcoller.it\/it\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pezcoller.it\/it\/wp-json\/wp\/v2\/comments?post=8416"}],"version-history":[{"count":1,"href":"https:\/\/www.pezcoller.it\/it\/wp-json\/wp\/v2\/pages\/8416\/revisions"}],"predecessor-version":[{"id":10215,"href":"https:\/\/www.pezcoller.it\/it\/wp-json\/wp\/v2\/pages\/8416\/revisions\/10215"}],"wp:attachment":[{"href":"https:\/\/www.pezcoller.it\/it\/wp-json\/wp\/v2\/media?parent=8416"}],"wp:term":[{"taxonomy":"folder","embeddable":true,"href":"https:\/\/www.pezcoller.it\/it\/wp-json\/wp\/v2\/folder?post=8416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}